Evaluating flow-diverting stents for treating cerebral aneurysms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness and safety of two types of flow-diverting stents, p64MW HPC and p48MW HPC, in treating cerebral aneurysms across multiple hospitals in Spain. It is an observational study that will analyze the success rates of the interventions, as well as the occurrence of hemorrhagic and thromboembolic complications over a 12-month follow-up period. The study utilizes commercially available devices and focuses on real-world clinical practices to gather data on patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients over 18 years old with incidental, symptomatic, and/or ruptured cerebral aneurysms.
* Signed informed consent by the patient or their representative.

Exclusion Criteria:

* Patients under 18 years of age.
* Absence of signed informed consent by the patient or their representative.
* Known, medically untreatable allergy to iodinated contrast.
* Pregnant women or those breastfeeding.

Where it's running

• Hospital Universitario de A Coruña
  A Coruña, Spain Recruiting
• Hospital Universitari Germans Trias I Pujol
  Badalona, Spain Recruiting
• Hospital Universitari Vall D Hebron
  Barcelona, Spain Recruiting
• Hospital Universitario de Burgos
  Burgos, Spain Recruiting
• Hospital Universitario de Donostia
  Donostia / San Sebastian, Spain Recruiting
• Hospital Universitario La Paz
  Madrid, Spain Recruiting

Study contacts

• Study coordinator: PEDRO VEGA VALDES, MD, PhD
• Email: peveval@yahoo.es
• Phone: 0034985108000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NIRS and BIS monitoring during cerebral aneurysm coiling under anesthesia

  This study tests whether continuous NIRS and BIS monitoring during endovascular aneurysm coiling under general anesthesia can help identify cerebral desaturation and its relationship to anesthetic depth and blood flow.

  Recruiting Dokuz Eylul University · Gaziantep · NCT07438275

• How heparins can interfere with argatroban blood tests

  This project will test whether remaining heparin in blood samples changes laboratory measurements of argatroban activity for adults treated with UFH or LMWH.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07302620

• Investigating factors related to intracranial aneurysms in China

  This study looks at what factors might cause or worsen brain aneurysms in people in China to help understand the risks better.

  Recruiting Zhujiang Hospital · Guangzhou · NCT06456814

• Real-world outcomes of MicroVention devices for intracranial aneurysm treatment

  This project collects real-world data to see how well commercially available MicroVention devices work for treating brain aneurysms in patients treated by their doctors.

  Recruiting at 27 sites Microvention-Terumo, Inc. · Walnut Creek, California and 26 other locations · NCT06215105

• Registry of brain-heart comorbidity in China

  This study is trying to build a big database to better understand and manage the connection between brain and heart problems in people across China.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality and 13 other locations · NCT05961748

• Investigating Clonal Hematopoiesis and Neutrophil Extracellular Traps in Venous Thrombosis

  This study is trying to see if certain blood changes are linked to repeated blood clots in younger people who don’t have the usual risk factors.

  Recruiting at 3 sites University Hospital, Bordeaux · Bordeaux and 6 other locations · NCT05711173

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.